Worthy Endeavor: Graphene Manufacturing Group Ships Fast-Charge Cells for Customer Testing
Graphene Manufacturing Group has begun shipping six-minute-charge battery cells for customer testing. Promising laboratory results now face the challenge of real-world performance, commercial adoption and production scalability.
Graphene Manufacturing Group (TSXV: GMG / OTCQX: GMGMF) has begun shipping its graphene aluminium-ion battery cells to potential customers, marking an important step toward commercial development.
On October 21, 2026, the Australian clean-technology company announced it had dispatched the first of more than 100 planned G®CELLS for independent evaluation. The approximately 1.5 Ah pouch cells are designed for six-minute charging, with potential applications in defence and heavy mobile equipment.
Shares closed at C$2.03 on October 22, down 5.14%, with approximately 115,000 shares traded.
The company manufactures graphene from natural gas and develops energy-saving coatings, lubricants and next-generation batteries. Its battery programme includes a joint development agreement with Rio Tinto and support from the Battery Innovation Center in Indiana.
Previous laboratory testing delivered promising results. The cells showed no performance reduction after 1,000 cycles at a six-minute charge-discharge rate, while energy density improved 48% to 58 Wh/kg. Energy efficiency reached 94%, compared with 64% for a tested lithium titanate oxide cell.
The next challenge is commercial validation. These cells remain pre-commercial samples, and performance under real-world customer conditions has yet to be established.
Financial pressure also remains. The company reported trailing revenue of approximately A$0.7 million and continued operating losses. Cash stood near A$10 million at June 30, supplemented by a US$10 million private placement completed in September.
What we’re watching: Customer testing results, improvements in energy density and progress toward battery technology readiness levels 7–8. Can GMG turn promising laboratory performance into commercial production orders without requiring substantial additional capital?
This is not an investment recommendation.
Comments